Literature DB >> 16213741

Allogeneic hematopoietic cell transplantation (HCT) following reduced-intensity conditioning in patients with acute leukemias.

Dietger Niederwieser1, Chiara Gentilini, Ute Hegenbart, Thoralf Lange, Cornelia Becker, Song-Yau Wang, Kristina Bartsch, Wolfram Pönisch, Martin Raida, Haifa Al-Ali.   

Abstract

The majority of patients with acute leukemia enter complete remission following induction therapy, but relapse despite consolidation and maintenance chemotherapy. Allogeneic hematopoietic cell transplantation (HCT) is the most effective consolidation therapy but unfortunately associated with high transplant-related mortality (TRM). In order to decrease TRM but still apply a graft-versus-tumor effect, allogeneic HCT protocols with reduced-intensity conditioning were developed and more than 5000 HCT, of which 1500 for acute leukemia, performed. Detailed information is available on more than 400 patients with acute leukemia. The results, summarized in this article, confirm that reduced-intensity preparative regimens lead to full donor chimerism and to generation of graft-versus-leukemia (GvL) effects with curative potential in older patients (>60 years). Prospective-controlled clinical trials are needed in younger patients to compare results of HCT after reduced-intensity conditioning to those of HCT with conventional conditioning.

Entities:  

Mesh:

Year:  2005        PMID: 16213741     DOI: 10.1016/j.critrevonc.2005.03.016

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  1 in total

1.  Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning-Eudract #: 2007-002420-15.

Authors:  Dietger Niederwieser; Vladan Vucinic; Saskia Hell; Madlen Jentzsch; Georg-Nikolaus Franke; Nadja Jäkel; Susann Schulze; Jeanett Edelmann; Kolja Nenoff; Nora Grieb; Veljko Jeremic; Michael Cross; Sabine Leiblein; Enrica Bach; Wolfram Pönisch; Haifa-Kathrin Al-Ali; Sebastian Schwind; Uwe Platzbecker; Thoralf Lange
Journal:  Bone Marrow Transplant       Date:  2022-02-18       Impact factor: 5.483

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.